DOW JONES21,636.78-915.39 -4.06%
S&P 5002,541.47-88.60 -3.37%
NASDAQ7,502.38-295.16 -3.79%

Goldman Sachs Downgrades Cellectis to Sell, Lowers Price Target to $11

Goldman Sachs analyst Salveen Richter downgrades Cellectis (NASDAQ:CLLS) from Neutral to Sell and lowers the price target from $15 to $11.

Benzinga · 03/06/2020 13:00

Goldman Sachs analyst Salveen Richter downgrades Cellectis (NASDAQ:CLLS) from Neutral to Sell and lowers the price target from $15 to $11.